CNSP · CNS Pharmaceuticals, Inc. · Documents

$3.62 +0.00 (+0.00%) At close · Nov 12

Market Cap

$5.29M

1.46M

Volume · Nov 12 2870 Avg daily vol (3M) 9663

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $15.85M 10-K filed Mar 31, 2026 Quarterly report FY2026 Q2 Net loss $2.59M 10-Q filed Aug 12, 2026 Latest results Financial results 8-K filed May 16, 2024

2026

Oct 2

Current report 8-K Events of Sep 30

Director or officer change, or executive pay, Shareholder vote results

CNS Pharmaceuticals, Inc. stockholders elected six directors, approved advisory executive compensation, ratified MaloneBailey, LLP, and authorized a 650,000-share increase in the 2020 Equity Plan, bringing authorized issuance to 765,061 shares.

Aug 25

Proxy statement DEFA14A

Proxy statement AI summary on its way

Aug 21

Proxy statement DEF 14A Meeting Sep 30, 2026

Proxy statement AI summary on its way

Aug 12

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $2.59M Diluted EPS -$0.38

Jul 2

Current report 8-K

Regulation FD disclosure AI summary on its way

May 19

Registration statement S-3

Registration statement AI summary on its way

May 14

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $4.94M Diluted EPS -$7.30

May 4

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Director or officer change, or executive pay AI summary on its way

Apr 30

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2025 AI summary on its way

Mar 31

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Net loss $15.85M Diluted EPS -$35.75

Mar 11

Current report 8-K

Regulation FD disclosure AI summary on its way

Mar 2

Current report 8-K Events of Feb 26

Director or officer change, or executive pay AI summary on its way

Feb 17

Current report 8-K Events of Feb 10

Director or officer change, or executive pay AI summary on its way

2025

Dec 17

Current report 8-K Events of Dec 16

Director or officer change, or executive pay

Nov 21

Current report 8-K Events of Nov 17

Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Nov 14

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Net loss $3.22M Diluted EPS -$5.76

Nov 12

Proxy statement DEFA14A

Proxy statement

Oct 28

Annual report to holders ARS

Annual report to holders

Oct 24

Proxy statement DEF 14A Meeting Nov 17, 2025

Proxy statement

Oct 10

Proxy statement PRE 14A Meeting Nov 17, 2025

Proxy statement

Aug 14

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Net loss $2.37M Diluted EPS -$6.42

Jul 22

Current report 8-K Events of Jul 17

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Jul 15

Current report 8-K

Regulation FD disclosure

May 15

Current report 8-K Events of May 13

Entered into a material agreement

May 15

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Net loss $4.3M Diluted EPS -$1.58

May 12

Registration statement S-1/A

Registration statement

Apr 30

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2024

Apr 14

Registration statement S-1

Registration statement

Apr 9

Current report 8-K

Regulation FD disclosure

Mar 31

Current report 8-K

Other events

Mar 31

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Net loss $14.86M Diluted EPS -$38.87

Mar 20

Current report 8-K

Other events

Feb 21

Current report 8-K Events of Feb 19

Change to shareholders' rights, Other events

Jan 3

Current report 8-K

Regulation FD disclosure, Other events

2024

Dec 11

Current report 8-K

Regulation FD disclosure

Dec 3

Current report 8-K Events of Nov 26

Shareholder vote results

Nov 15

Proxy statement DEFR14A

Proxy statement

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Net loss $5.61M Diluted EPS -$0.25

Nov 1

Current report 8-K Events of Oct 30

Other events

Oct 28

Proxy statement DEF 14A Meeting Nov 26, 2024

Proxy statement

Oct 24

Current report 8-K Events of Oct 23

Entered into a material agreement, Other events

Oct 23

Current report 8-K

Other events

Oct 15

Proxy statement PRE 14A Meeting Nov 26, 2024

Proxy statement

Sep 18

Current report 8-K Events of Sep 12

Delisting notice or listing transfer

Sep 12

Current report 8-K Events of Sep 10

Delisting notice or listing transfer

Aug 14

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Net loss $2.53M Diluted EPS -$6.72

Aug 7

Current report 8-K Events of Aug 6

Other events

Jul 30

Current report 8-K Events of Jul 29

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Jul 30

Current report 8-K

Other events

Jul 26

Current report 8-K

Entered into a material agreement

Showing 1–50 of 170 documents

Key facts CIK 1729427 CUSIP 18978H508 13F (30d) 9 filings 5 filers Visit website Investor relations